GI Dynamics (ASX:GID) said Australian type 2 diabetes patients treated with its EndoBarrier therapy were able to reduce or eliminate insulin therapy. [ + ]

If you are a professional working in the therapeutics sector, don't miss the 2014 ARCS Scientific Congress to be held in Sydney at the beginning of June. [ + ]

QUT and Wollongong University, along with two European Institutes, are the first to offer a course in biofabrication. [ + ]

The biotech sector is regrouping after the bruising Federal Budget on Tuesday night delivered a round of cuts for biotechnology, including measures to reduce the R&D Tax Incentive and abolish the Innovation Investment Fund (IIF) and Commercialisation Australia (CA). [ + ]

Clinuvel Pharmaceuticals (ASX:CUV) has closed a $7.2m private placement, to help fund development of Scenesse in vitiligo and a post-marketing study of the drug in EPP. [ + ]

Neurodegenerative disease expert professor Ira Shoulson has joined the Prana Biotechnology (ASX:PBT) board to help the company develop PBT2 as a treatment for Huntington disease. [ + ]

Scientific equipment supplier AXT has signed an exclusive distribution agreement with Delmic, a Dutch company specialising in fluorescent/SEM (SECOM) and cathodoluminescent/SEM (SPARC) correlative microscopy technology. [ + ]

GlaxoSmithKline has opened nominations for the 2014 GSK Award for Research Excellence (ARE). The prestigious award recognises outstanding achievements in medical research and facilitates career development with potential importance to human health and Australian research. [ + ]

Life Sciences Queensland Limited (LSQ) recently recognised its ongoing interaction with NZBIO with the signing of a memorandum of understanding (MoU). [ + ]

Dimerix has hired former Calzada chairman David Franklyn as a non-executive director, and veteran scientist Dr Brian Richardson as part of its scientific advisory team. [ + ]

A new 3D-printed device, developed by CSIRO in collaboration with dental company Oventus, is set to end the suffering for thousands of sleep apnoea patients. [ + ]

A new research initiative in tropical health and medicine has received $42 million in Australian Research Council funding. [ + ]

Reports of potential reduction of industry-support programs, on the back of the Commission of Audit report, are causing angst in the biotech sector as the industry fears decisions that could seriously damage Australia's hard-won momentum in innovation. [ + ]

Early work has begun on the ANM Project - a $168 million plan to build a nuclear medicine manufacturing plant and waste treatment plant to treat by-products for permanent, safe storage. [ + ]

Admedus (ASX:AHZ) has raised $8m in a placement, with plans to put the proceeds towards expanding its US and EU reach for CardioCel and to help fund a phase II trial of its HSV-2 vaccine. [ + ]